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Risk of Cardiometabolic Disease and All-Cause Mortality in Female
Survivors of Domestic Abuse
Joht Singh Chandan, MFPH; Tom Thomas, MBBS; Caroline Bradbury-Jones, PhD; Julie Taylor, PhD;* Siddhartha Bandyopadhyay, PhD;*
Krishnarajah Nirantharakumar, MD*
Background-—Domestic abuse (DA) against women is a global public health problem. Although the possible health burden could be
substantial, the associations between DA and subsequent cardiometabolic disease (cardiovascular disease, hypertension, and type
2 diabetes mellitus) and all-cause mortality are poorly understood.
Methods and Results-—This retrospective cohort study consisted of UK-based primary care patients between January 1, 1995, to
December 1, 2017. Overall, 18 547 women exposed to DA were matched to 72 231 unexposed women by age and lifestyle
factors. The main outcomes, presented as adjusted incidence rate ratios (IRRs), were the risk of developing cardiovascular disease,
hypertension, type 2 diabetes mellitus, and all-cause mortality. In total, 181 exposed women experienced a cardiovascular disease
event compared with 644 of the unexposed control group, relating to an increased adjusted IRR of 1.31 (95% CI, 1.11–1.55;
P=0.001). There was also an increased risk of subsequent type 2 diabetes mellitus (adjusted IRR: 1.51; 95% CI, 1.30–1.76;
P<0.001) and all-cause mortality (adjusted IRR: 1.44; 95% CI, 1.24–1.67; P<0.001) following exposure to DA. This observation was
not seen with hypertension (adjusted IRR: 0.99; 95% CI, 0.88–1.12; P=0.873).
Conclusions-—There is an increased risk of subsequent cardiovascular disease, type 2 diabetes mellitus, and all-cause mortality in
female survivors of DA. However, there is no association with the development of hypertension in this group, in keeping with
previous literature. Considering the high prevalence of DA, clinicians should be made aware of the disproportionally increased risk
and thus are encouraged to manage modifiable risk factors actively in this group. ( J Am Heart Assoc. 2020;9:e014580. DOI: 10.
1161/JAHA.119.014580.)
Key Words: cardiovascular disease • domestic abuse • epidemiology • hypertension • type 2 diabetes mellitus
D omestic abuse (DA) against women is a global publichealth problem and a violation of human rights.1 It is
defined by the UK government as “any incident or patterns of
incidents of controlling, coercive, threatening behavior,
violence or abuse between those aged 16 or over who are,
or have been, intimate partners or family members regardless
of gender or sexuality.”2 The UK prevalence of lifetime
exposure to DA in the female population is estimated to be
27.1%.3
Population-based studies have identified an association
between being a survivor of DA and a variety of physical and
psychological consequences in this group.4–7 A previous
systematic review8 assessed the impact of being a survivor of
DA and the development of cardiovascular disease (CVD) and
hypertension. This review8 included 13 cross-sectional stud-
ies and 2 prospective studies (both examining the develop-
ment of hypertension). The included cross-sectional studies
provided conflicting evidence of a potential association
between exposure to DA and the development of CVD. The
largest cross-sectional study9 (n=70 156) included both male
and female participants and found a higher risk of developing
self-reported coronary heart disease and heart attacks among
DA survivors. This result was consistent with findings from a
more recent small (n=151) study in a Polish population10 for
which self-reported DA was associated with a 6-fold increased
risk of developing ischemic heart disease (IHD). In contrast, a
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cross-sectional study11 conducted in South Africa suggested
that survivors of DA were not at increased risk of developing
heart disease or heart attacks. More recent systematic
reviews examining physical outcomes of DA survivors5,12 have
not identified any global cohort study designed to assess CVD
risk following DA exposure.
Interestingly, despite the possible association with CVD
development, many studies report no association between DA
and the subsequent development of hypertension,11,13–17
suggesting that hypertension may not be a mediating factor in
the relationship between DA and CVD. The NHSII (Nurses’
Health Study II)18 was a prospective study that demonstrated
being a victim of severe emotional abuse is associated with
the development of hypertension, but this relationship was
not present in survivors of sexual and violent forms of DA. The
other relevant prospective study19 was conducted in Norway
(N=5593 women) and discerned a positive association
between physical and sexual DA with the subsequent use of
antihypertensive drugs. However, neither of these prospective
studies used clinical CVD end points such as IHD, stroke,
transient ischemic attack (TIA), peripheral vascular disease, or
heart failure.
Similar to CVD, there is sparse literature assessing the
relationship between DA and the development or incidence of
type 2 diabetes mellitus (T2DM). The association between
childhood abuse and development of T2DM in later life20–22
has been well documented; however, few studies have
explored this association in the DA population. The NHSII
was one of the few studies investigating this link and
identified a 61% adjusted increased risk in the incidence of
T2DM in DA survivors who had undergone severe psycholog-
ical abuse, but this finding was not statistically significant in
survivors of physical and sexual abuse.23
The pathophysiologic link between DA and cardiometabolic
disease is complex and unclear. It is thought that the acute
and sustained elevated stress response triggered by DA can
compromise the neuroendocrine and immune systems and
induce changes in brain structure, leading to an increased risk
of a variety of physical and psychological disorders.1 Similar
to survivors of childhood abuse,24 female survivors of DA25
appear to have elevated levels of CRP (C-reactive protein) in
their plasma and salivary glands that may be associated with
the development of cardiometabolic disease26,27; however,
little research on this topic has been conducted in a
population exposed to DA. A recent consensus on the
association between childhood adversity and subsequent
cardiometabolic development considered that the relationship
may be tied to 3 pathways that may occur following abuse:
adoption of poor lifestyle behaviors (physical inactivity, poor
diet, disrupted sleep, substance misuse, and smoking); mental
ill health; and alteration of immune, metabolic, neuroen-
docrine, and autonomic nervous systems.28 It is likely that
similar pathways may be mediating the relationship between
DA and cardiometabolic disease. For example, previous
research has identified that DA survivors experience higher
rates of smoking, obesity, and excessive alcohol use
compared with the general population.5,29–33 However, pre-
vious studies have not been able to address the impact of
these lifestyle factors.
Globally, cardiometabolic disease still remains an impor-
tant, albeit preventable, cause of mortality.34 Literature
exploring the association between DA and mortality risk is
scarce. Of the available evidence, it is clear that being a victim
of DA is associated with a disproportionally increased risk of
homicide and nonaccidental injuries as causes of death.35,36
However, there is absence of evidence examining the
association between DA and all-cause mortality risk compared
with the general population.
It is evident that no previous cohort study has investigated
the relationship between exposure to DA and the develop-
ment of CVD and all-cause mortality in the female population,
and only a few studies have explored the relationship between
DA and the development of hypertension and T2DM in a
cohort setting. Consequently, considering the sizeable preva-
lence of DA and the public health burden posed by
cardiometabolic disease, we aimed to explore the relationship
Clinical Perspective
What Is New?
• The global health burden of domestic abuse (DA) is
substantial and a key cause of morbidity and mortality for
women; however, few studies have explored the relationship
between DA and the subsequent development of car-
diometabolic disease or all-cause mortality.
• We demonstrate 31%, 51%, and 44% increased risk of
subsequent cardiovascular disease, type 2 diabetes mellitus
and all-cause mortality following consideration of important
lifestyle factors.
• There is no clear increased risk of hypertension following DA
in line with previous literature.
What Are the Clinical Implications?
• Considering the high prevalence of DA among women,
clinicians should be made aware of the disproportionally
increased risk and thus are encouraged to consider the
need for intervention in this cohort.
• Women exposed to DA also appear to have a higher burden
of lifestyle risk factors such as smoking and excessive
alcohol use compared with the general population.
• This lifestyle risk may play a role in the described
association and will require a coordinated public health
approach to manage.
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between DA and cardiometabolic disease (CVD, hypertension,
and T2DM) alongside mortality.
Methods
The anonymized data that support the findings of this study
are available from the senior author (k.nirantha-
ran@bham.ac.uk). However, this will be subject to approval
from the data providers and data owners (IQVIA and
Cegedim). Ethics approval: anonymized data were used
throughout the study, provided by the data provider IQVIA
to the University of Birmingham. Studies using the Health
Improvement Network (THIN) database have had initial ethics
approval from the NHS South-East Multicentre Research
Ethics Committee, subject to prior independent scientific
review. The Scientific Review Committee (IMS Health)
approved the study protocol (SRC Reference Number:
SRC18THIN034) before its undertaking. Informed consent
was not required in this study as the data were anonymized.
Study Design and Data Source
This population-based, retrospective, open, cohort study using
the Health Improvement Network (THIN) database compared
female patients coded with previous exposure of DA with
female patients not coded to have experienced DA. The THIN
database consists of UK electronically recorded person-level
medical records derived from >750 general practices and is
considered to be representative of the UK population.37
Patient information is entered into electronic record software
that uses Read codes.38 Diagnosis and clinical presentations
are represented in the Read code hierarchy system. Other
available data in the database relate to demographic,
prescription, biochemistry results, and mortality data. To
reduce underrecording of events, individual practices were
included 12 months following their electronic practice system
was installed or from the practice’s acceptable mortality
recording date.
Study Population
Women noted by general practitioners to have been
exposed to DA (exposed cohort) were identified during
the study period (January 1, 1995, to December 1, 2017).
The index date in the exposed group was stated to be the
first documentation of an DA Read code once a patient was
eligible to take part in the study during the study period or
the study start date for patients with a previous record of
DA. An open cohort study allows for patients to enter and
exit the study at different time points, with each individual
patient contributing only person-years of follow-up from the
time of cohort entry (index date) to the time she leaves the
cohort (exit date).
Each exposed woman was matched to up to 4 women who
had noDARead code from randomgeneral practitioner practices
in the data set (unexposed cohort). Controls from the unexposed
group were matched individually to cases based on age at index
date (1 year), body mass index (to within 2 kg/m2), smoking
status, and Townsend deprivation score39 at baseline.
To mitigate immortality time bias,40 the same index date
was assigned to the corresponding unexposed patient. The
follow-up period for each patient was from the index date until
the exit date. Exit date is defined as the earliest of the
following dates: study end date, last date of data collection
from a given general practice, date the patient transferred
from general practice, date of death, or date the outcome of
interest occurred.
The primary outcome was the development of car-
diometabolic disease, exploring the outcomes of CVD (IHD,
heart failure, peripheral vascular disease, and stroke or TIA
during the observation period), hypertension, and T2DM as
identified through Read codes. In the UK primary setting, there is
a mandatory requirement to maintain an accurate register of
CVD, hypertension, and T2DM patients that is further incen-
tivized through the national Quality and Outcome Framework
system recording an individual’s identification and management
of these conditions.41 All patients with a recorded code of DA
who were eligible during the study period with their correspond-
ing controls were included in the risk calculation for all-cause
mortality. The details for these patients are highlighted in
Table 1. However, when examining each outcome of interest
(CVD, hypertension, or T2DM), patients were excluded from the
study if they had a diagnosis relating to the corresponding
condition before the index date of the study. For example,
patients highlighted in Table 1 with existing diagnoses of
hypertension at baseline were excluded from the main cohort
when we examined the risk of developing hypertension.
Covariates known to affect the development of CVD,
hypertension, or T2DM were included in the study population
baseline data. These included body mass index, Townsend
deprivation score, the use of lipid-lowering medications,
smoking status, hypertension and diabetes mellitus, alcohol
excess, and comorbidity identified through the Charlson
comorbidity index.42
Read code lists for exposure, outcomes, and covariates are
provided in Table S1. Table S2 contains the RECORD
(Reporting of studies conducted using observational routi-
nely-collected data) reporting checklist for this study.43
Statistical Analysis
Categorical baseline data were described using proportions,
and parametric continuous variables were described using
meanSD. Missing data are described in the baseline
characteristics (Table 1).
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The number of outcomes in each group is described and
then an incidence rate (IR) per 1000 person-years was
calculated. Poisson regression was then used to calculate an
IR ratio (IRR) for each outcome of interest, offsetting for
person-years of follow-up. The IRR was adjusted for known
covariates independently affecting the outcome of interest
(eg, age, deprivation, body mass index, use of lipid-lowering
medications, smoking status, hypertension, and T2DM [for
individual components of CVD] and alcohol excess and
Charlson comorbidity score [for mortality]), and an adjusted
IRR for each outcome of interest was calculated. IRRs were
calculated with 95% CIs, and statistical significance was set at
P<0.05. In addition, for the calculation of the risk of individual
components of CVD, a composite CVD risk was calculated,
composed of the risk of developing IHD, stroke or TIA, heart
failure, and peripheral vascular disease.
Stata version 14.2 software (StataCorp) was used to
conduct all analyses throughout the study. This particular
study obtained study specific approval from the scientific
review committee in May 2018 (SRC18THIN034).
Results
Baseline Characteristics
A total of 18 547 women who had experienced DA were
matched to 73 231 unexposed women as controls. The mean
length of follow-up was shorter at 2.22.3 years in the
exposed group compared with 3.12.7 years in the unex-
posed group. This result was due to women in the exposed
group transferring practice more frequently than those in the
unexposed group. The mean age (37 years) was similar in
both exposed and unexposed groups. Given the matching
process, body mass index, smoking, and deprivation levels
were similar between groups. Of particular note, both groups
had high prevalence of smoking (44.7%) and high levels of
deprivation compared with the national UK average. Excessive
drinking at baseline was more prevalent at 10.1% in the
exposed group compared with 3.5% in the unexposed group.
The exposed group at baseline had higher proportion of
patients with T2DM, greater comorbidity, higher prevalence of
hypertension, and more use of lipid-lowering medications.
Baseline characteristics are presented in Table 1.
Association Between DA and Subsequent
Development of Cardiometabolic Disease
During the study period, 181 women (IR: 3.1 per 1000 person-
years) in the exposed group compared with 644 women (IR:
2.3 per 1000 person-years) in the unexposed group developed
a CVD outcome. This translated into an increased adjusted
IRR of composite CVD (1.31; 95% CI, 1.11–1.55; P=0.001).
Specifically, the DA group had a significantly higher risk of
developing IHD (1.40; 95% CI, 1.09–1.79; P=0.007) and
stroke or TIA (1.29; 95% CI, 1.02–1.63; P=0.035). There were
Table 1. Baseline Characteristics
Exposed Group Unexposed Group
Patients, n 18 547 73 231
Follow-up period (person-years) 2.22.3 3.12.7
Age, y 36.912.5 36.912.4
Body mass index
<25 7916 (42.7) 31 692 (42.3)
25–30 3999 (21.6) 15 940 (21.8)
>30 3568 (19.2) 13 680 (18.7)
Not available 3064 (16.5) 11 919 (16.3)
Current smoking 8096 (44.7) 32 064 (44.7)
Hypertension 1106 (6.0) 4200 (5.7)
Lipid-regulating medications 955 (5.2) 3418 (4.7)
T2DM 463 (2.5) 1431 (2.0)
Drinking status
Nondrinker 5149 (27.8) 13 709 (18.7)
Drinker not excess 8353 (45.0) 41 993 (57.3)
Excessive drinker 1870 (10.1) 2558 (3.5)
Not available 3175 (17.1) 14 971 (20.4)
Townsend index
(Least deprived) 1 1773 (9.6) 8303 (11.3)
2 2104 (11.3) 9553 (13.1)
3 3149 (17.0) 13 695 (18.7)
4 4215 (22.7) 16 818 (23.0)
5 4266 (23.0) 16 110 (22.0)
Not available 3040 (16.4) 8752 (12.0)
Charlson comorbidity index
0 (Least comorbid) 13 569 (73.2) 57 030 (77.9)
1 4130 (22.3) 13 352 (18.2)
2 571 (3.1) 1983 (2.7)
3 170 (0.9) 542 (0.7)
≥4 108 (0.6) 324 (0.4)
CVD at baseline
IHD 199 (1.1) 539 (0.7)
Stroke/TIA 208 (1.2) 488 (0.7)
Heart failure 24 (0.1) 109 (0.2)
Peripheral vascular disease 44 (0.2) 136 (0.2)
All CVD 413 (2.2) 1116 (1.5)
Data are shown as meanSD or n (%) except as noted. CVD indicates cardiovascular
disease; IHD, ischemic heart disease; TIA indicates transient ischemic attack; T2DM,
type 2 diabetes mellitus.
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not statistically significant differences between the likelihood
of developing heart failure or peripheral vascular disease.
Overall, 316 women in the exposed group developed
hypertension (IR: 5.7 per 1000 person-years) compared with
1496 women in the unexposed group (IR: 5.6 per 1000 person-
years). There was no association observed between DA and
hypertension (IRR: 0.99; 95% CI, 0.88–1.12; P=0.873). In total,
222 women (IR: 3.8 per 1000 person-years) in the exposed
group compared with 678 women (IR: 2.4 per 1000 person-
years) in the unexposed group developed T2DM. The risk of
developing T2DM was found to be higher in the exposed cohort
than in the unexposed cohort (IRR: 1.51; 95% CI, 1.30–1.76;
P<0.001). These results are presented in Figure and Table 2.
Mortality Analysis
Table 3 demonstrates the variation in risk of all-cause
mortality between the exposed and unexposed groups. A
total of 248 patients in the DA group died during the study
period compared with 700 in the unexposed group. This
relates to an IR per 1000 person-years of 6.0 and 3.1 between
the DA and unexposed groups, respectively. Following
adjustment, this translated into an IRR of 1.44 (95% CI,
1.24–1.67; P<0.001).
Discussion
Summary of Key Results
After matching and adjusting for key lifestyle factors, this
study found that women who were coded with exposure to DA
were at a higher risk of developing CVD (particularly IHD and
stroke or TIA) and T2DM than those not coded for exposure to
DA. In addition, the risk of all-cause mortality was higher in
the group of women who had experienced DA. However, there
was no association between exposure to DA and the
development of hypertension.
Relationship to Current Literature
To the authors knowledge, this cohort study is the first to
assess the CVD outcomes and all-cause mortality risk
associated with DA and has added to the literature exploring
the association between DA and the development of hyper-
tension and T2DM.
Because no cohort study has previously been designed to
compare the IR of CVD in the cohort of women who have
experienced DA, it is difficult to directly compare this study
with studies that demonstrate an increased risk of developing
of CVD outcomes.19,44 However, this study supports the
suggestion that exposure to DA increases the risk of
developing CVD suggested by previously cross-sectional
studies.8 In particular, our study is consistent with the
assertion that DA may particularly correlate with the devel-
opment of IHD.8,10 Interestingly, in agreement with previous
work (cross-sectional studies13–17 and 1 prospective study18),
our study supports no statistical association between being a
survivor of DA and hypertension. Our study also demonstrates
an association between DA and T2DM. This relationship
mirrors the positive association between DA and T2DM
previously reported in the NHSII23 in survivors of severe
psychological forms of DA.
This study made efforts to account for the impact of
lifestyle choices on the development of cardiometabolic
disease by matching similar patients. Previous studies
suggested that women exposed to DA had high rates of
smoking, alcohol use, and obesity,5,29–33 which was clearly
demonstrated in our study. Both cohorts had high baseline
rates of smoking (44.7%), and more patients in the DA cohort
were excessive drinkers. Interestingly, however, following
matching and adjustment for these factors, there still
appeared to be a relationship between DA and car-
diometabolic disease. This finding suggests that lifestyle
risk factors may not be the sole explanation for the
observed increased risk of cardiometabolic disease in this
population. Further investigation must be conducted into
Figure. Cardiometabolic disease risk. aIRR indicates adjusted incidence rate ratio.
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other possible mediating pathways that are responsible for
this relationship.
Similarly, because there have been no cohorts examining
the association between all-cause mortality and DA exposure,
it is not possible to compare the IR in our study with others.
We show an increased mortality risk associated with DA, and
this may correlate with literature identifying that victims of DA
are at an increased risk of violent injury that may lead to
death.35,36 However, it may also raise the possibility that
there is an increased burden of CVD and other morbidities
that may increase mortality.
Study Limitations
The use of a primary care database to undertake retrospective
analysis relies on the correct coding of Read codes by general
practitioners. Therefore, the validity of codingwill be affected by
differing coding practices. An important limitation to note is that
the overall number of women experiencing DA appears to be
extremely low in this study population compared with the
estimates provided previously in the United Kingdom.3 Conse-
quently, it is possible that women of the unexposed group may
actually have experienced DA but were misclassified as
unexposed. This possible misclassification bias may lead to
underestimation of the true effect size. Similarly, we may have
identified only women with severe DA, which may result in an
overestimate of the effect size. To minimize this risk, we
attempted to use multiple codes relating to DA to capture as
many patients as possible. It is worth highlighting that the
underrecording of DA in a primary care setting suggests the
importance of ensuring that clinicians make a concerted effort
to ask at-risk patients about a history of abuse.
Given the nature of the data collected, we were unable to
assess for the dose relationship between the severity of DATa
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Table 3. Risk of Mortality in the Exposed and Unexposed
Groups
Exposed Unexposed
Patients, n 18 547 73 231
No. of outcomes 248 700
Person-years 41 213 225 438
IR (per 1000 person-years) 6.0 3.1
IRR (95% CI)* 1.94 (1.68–2.24)
P value <0.001
aIRR (95% CI)† 1.44 (1.24–1.67)
P value <0.001
aIRR indicates adjusted incidence rate ratio; IR, incidence rate; IRR, incidence rate ratio.
*Unadjusted incidence rate ratio.
†Adjusted for body mass index, age, sex, smoking status, diabetes mellitus status, lipid-
lowering drug use, hypertension, Charlson comorbidity score, alcohol status, and
Townsend deprivation score.
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and CVD, hypertension, and T2DM, which could have provided
further useful information. It is possible, for example, that
more severe abuse may be correlated with worse car-
diometabolic outcomes. It is also important to identify that
although we matched women’s lifestyle choices at baseline, it
would be interesting to identify whether exposure to DA leads
to poorer lifestyle choices in the future, which also may
mediate the described effect size.
Conclusions
This is the first cohort study to demonstrate an association
between DA and the development of CVD. This study has
reaffirmed the relationship between exposure to DA and the
development of T2DM, even after consideration of the impact
of contributing lifestyle risk factors, and identifies this
population as having higher risk of all-cause mortality. This
cohort study also supports previous research demonstrating
no association between the development of hypertension and
being a female survivor of DA. However, this result needs to
be viewed in light of the limitations of the study design.
Regardless, given the sizeable population that these results
may affect, physicians should pay particular notice to
managing risk factors for CVD and T2DM in this group.
Further studies in other cohorts are needed to confirm this
relationship, and basic scientific research is required to
understand the biological plausibility of the associations
between DA exposure and the subsequent development of
cardiometabolic disease.
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Table S1. Read codes for domestic abuse, outcomes, baseline data and co-variates. 
 
Domestic abuse 
 
Clinical 
Code Description 
14X3.00 History of domestic violence 
14X8.00 Victim of domestic violence 
14XD.00 History of domestic abuse 
14XE.00 History of being victim of domestic violence 
14XG.00 Victim of domestic abuse 
 
 
Type 2 Diabetes 
 
Clinical 
Code 
Description 
C10..00 Diabetes mellitus 
C100.00 Diabetes mellitus with no mention of complication 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C100111 Maturity onset diabetes 
C100112 Non-insulin dependent diabetes mellitus 
C100z00 Diabetes mellitus NOS with no mention of complication 
C101.00 Diabetes mellitus with ketoacidosis 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C101y00 Other specified diabetes mellitus with ketoacidosis 
C101z00 Diabetes mellitus NOS with ketoacidosis 
C102.00 Diabetes mellitus with hyperosmolar coma 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C102z00 Diabetes mellitus NOS with hyperosmolar coma 
C103.00 Diabetes mellitus with ketoacidotic coma 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C103y00 Other specified diabetes mellitus with coma 
C103z00 Diabetes mellitus NOS with ketoacidotic coma 
C104.00 Diabetes mellitus with renal manifestation 
C104.11 Diabetic nephropathy 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C104y00 Other specified diabetes mellitus with renal complications 
C104z00 Diabetes mellitus with nephropathy NOS 
C105.00 Diabetes mellitus with ophthalmic manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
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C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
C106.00 Diabetes mellitus with neurological manifestation 
C106.11 Diabetic amyotrophy 
C106.12 Diabetes mellitus with neuropathy 
C106.13 Diabetes mellitus with polyneuropathy 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C106y00 Other specified diabetes mellitus with neurological comps 
C106z00 Diabetes mellitus NOS with neurological manifestation 
C107.00 Diabetes mellitus with peripheral circulatory disorder 
C107.11 Diabetes mellitus with gangrene 
C107.12 Diabetes with gangrene 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107200 Diabetes mellitus, adult with gangrene 
C107400 NIDDM with peripheral circulatory disorder 
C107y00 Other specified diabetes mellitus with periph circ comps 
C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
C108y00 Other specified diabetes mellitus with multiple comps 
C108z00 Unspecified diabetes mellitus with multiple complications 
C109.00 Non-insulin dependent diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
C109.12 Type 2 diabetes mellitus 
C109.13 Type II diabetes mellitus 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
C109011 Type II diabetes mellitus with renal complications 
C109012 Type 2 diabetes mellitus with renal complications 
C109100 
Non-insulin-dependent diabetes mellitus with ophthalm 
comps 
C109111 Type II diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109311 Type II diabetes mellitus with multiple complications 
C109312 Type 2 diabetes mellitus with multiple complications 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109411 Type II diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109511 Type II diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
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C109611 Type II diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109711 Type II diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109800 Reaven's syndrome 
C109900 
Non-insulin-dependent diabetes mellitus without 
complication 
C109911 Type II diabetes mellitus without complication 
C109912 Type 2 diabetes mellitus without complication 
C109A00 
Non-insulin dependent diabetes mellitus with 
mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
C109A12 Type 2 diabetes mellitus with mononeuropathy 
C109B00 
Non-insulin dependent diabetes mellitus with 
polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C109B12 Type 2 diabetes mellitus with polyneuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109C11 Type II diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C109D00 
Non-insulin dependent diabetes mellitus with hypoglyca 
coma 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109E11 Type II diabetes mellitus with diabetic cataract 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109F11 Type II diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109G11 Type II diabetes mellitus with arthropathy 
C109G12 Type 2 diabetes mellitus with arthropathy 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10A.00 Malnutrition-related diabetes mellitus 
C10A.11 Jamaica type diabetes 
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C10A000 Malnutrition-related diabetes mellitus with coma 
C10A100 Malnutrition-related diabetes mellitus with ketoacidosis 
C10A200 Malnutrition-related diabetes mellitus with renal complicatn 
C10A300 Malnutrit-related diabetes mellitus wth ophthalmic complicat 
C10A400 Malnutrition-related diabetes mellitus wth neuro complicatns 
C10A500 Malnutritn-relat diabetes melitus wth periph circul complctn 
C10A600 Malnutrition-related diabetes mellitus with multiple comps 
C10A700 Malnutrition-related diabetes mellitus without complications 
C10AW00 Malnutrit-related diabetes mellitus with unspec complics 
C10AX00 Malnutrit-relat diabetes mellitus with other spec comps 
C10B.00 Diabetes mellitus induced by steroids 
C10B000 Steroid induced diabetes mellitus without complication 
C10C.00 Diabetes mellitus autosomal dominant 
C10C.11 Maturity onset diabetes in youth 
C10D.00 Diabetes mellitus autosomal dominant type 2 
C10D.11 Maturity onset diabetes in youth type 2 
C10ER00 Latent autoimmune diabetes mellitus in adult 
C10F.00 Type 2 diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10F311 Type II diabetes mellitus with multiple complications 
C10F400 Type 2 diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F500 Type 2 diabetes mellitus with gangrene 
C10F511 Type II diabetes mellitus with gangrene 
C10F600 Type 2 diabetes mellitus with retinopathy 
C10F611 Type II diabetes mellitus with retinopathy 
C10F700 Type 2 diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C10F800 Reaven's syndrome 
C10F811 Metabolic syndrome X 
C10F900 Type 2 diabetes mellitus without complication 
C10F911 Type II diabetes mellitus without complication 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
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C10FB11 Type II diabetes mellitus with polyneuropathy 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C10FF11 Type II diabetes mellitus with peripheral angiopathy 
C10FG00 Type 2 diabetes mellitus with arthropathy 
C10FG11 Type II diabetes mellitus with arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FK11 Hyperosmolar non-ketotic state in type II diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FN11 Type II diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FP11 Type II diabetes mellitus with ketoacidotic coma 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10FQ11 Type II diabetes mellitus with exudative maculopathy 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10FR11 Type II diabetes mellitus with gastroparesis 
C10FS00 Maternally inherited diabetes mellitus 
C10G.00 Secondary pancreatic diabetes mellitus 
C10G000 Secondary pancreatic diabetes mellitus without complication 
C10H.00 Diabetes mellitus induced by non-steroid drugs 
C10H000 DM induced by non-steroid drugs without complication 
C10J.00 Insulin autoimmune syndrome 
C10J000 Insulin autoimmune syndrome without complication 
C10K.00 Type A insulin resistance 
C10K000 Type A insulin resistance without complication 
C10L.00 Fibrocalculous pancreatopathy 
C10L000 Fibrocalculous pancreatopathy without complication 
C10M.00 Lipoatrophic diabetes mellitus 
C10M000 Lipoatrophic diabetes mellitus without complication 
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C10N.00 Secondary diabetes mellitus 
C10N000 Secondary diabetes mellitus without complication 
C10N100 Cystic fibrosis related diabetes mellitus 
C10P.00 Diabetes mellitus in remission 
C10P100 Type II diabetes mellitus in remission 
C10P111 Type 2 diabetes mellitus in remission 
C10y.00 Diabetes mellitus with other specified manifestation 
C10y100 Diabetes mellitus, adult, + other specified manifestation 
C10yy00 Other specified diabetes mellitus with other spec comps 
C10yz00 Diabetes mellitus NOS with other specified manifestation 
C10z.00 Diabetes mellitus with unspecified complication 
C10z100 Diabetes mellitus, adult onset, + unspecified complication 
C10zy00 Other specified diabetes mellitus with unspecified comps 
C10zz00 Diabetes mellitus NOS with unspecified complication 
 
Ischaemic Heart Disease 
 
Clinical 
Code Description 
G3...00 Ischaemic heart disease 
G3...11 Arteriosclerotic heart disease 
G3...12 Atherosclerotic heart disease 
G3...13 IHD - Ischaemic heart disease 
G30..00 Acute myocardial infarction 
G30..11 Attack - heart 
G30..12 Coronary thrombosis 
G30..13 Cardiac rupture following myocardial infarction (MI) 
G30..14 Heart attack 
G30..15 MI - acute myocardial infarction 
G30..16 Thrombosis - coronary 
G30..17 Silent myocardial infarction 
G300.00 Acute anterolateral infarction 
G301.00 Other specified anterior myocardial infarction 
G301000 Acute anteroapical infarction 
G301100 Acute anteroseptal infarction 
G301z00 Anterior myocardial infarction NOS 
G302.00 Acute inferolateral infarction 
G303.00 Acute inferoposterior infarction 
G304.00 Posterior myocardial infarction NOS 
G305.00 Lateral myocardial infarction NOS 
G306.00 True posterior myocardial infarction 
G307.00 Acute subendocardial infarction 
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G307000 Acute non-Q wave infarction 
G307100 Acute non-ST segment elevation myocardial infarction 
G308.00 Inferior myocardial infarction NOS 
G309.00 Acute Q-wave infarct 
G30A.00 Mural thrombosis 
G30B.00 Acute posterolateral myocardial infarction 
G30X.00 Acute transmural myocardial infarction of unspecif site 
G30X000 Acute ST segment elevation myocardial infarction 
G30y.00 Other acute myocardial infarction 
G30y000 Acute atrial infarction 
G30y100 Acute papillary muscle infarction 
G30y200 Acute septal infarction 
G30yz00 Other acute myocardial infarction NOS 
G30z.00 Acute myocardial infarction NOS 
G31..00 Other acute and subacute ischaemic heart disease 
G310.00 Postmyocardial infarction syndrome 
G310.11 Dressler's syndrome 
G311.00 Preinfarction syndrome 
G311.11 Crescendo angina 
G311.12 Impending infarction 
G311.13 Unstable angina 
G311.14 Angina at rest 
G311000 Myocardial infarction aborted 
G311011 MI - myocardial infarction aborted 
G311100 Unstable angina 
G311200 Angina at rest 
G311300 Refractory angina 
G311400 Worsening angina 
G311500 Acute coronary syndrome 
G311z00 Preinfarction syndrome NOS 
G312.00 Coronary thrombosis not resulting in myocardial infarction 
G31y.00 Other acute and subacute ischaemic heart disease 
G31y000 Acute coronary insufficiency 
G31y100 Microinfarction of heart 
G31y200 Subendocardial ischaemia 
G31y300 Transient myocardial ischaemia 
G31yz00 Other acute and subacute ischaemic heart disease NOS 
G32..00 Old myocardial infarction 
G32..11 Healed myocardial infarction 
G32..12 Personal history of myocardial infarction 
G33..00 Angina pectoris 
G330.00 Angina decubitus 
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G330000 Nocturnal angina 
G330z00 Angina decubitus NOS 
G331.00 Prinzmetal's angina 
G331.11 Variant angina pectoris 
G332.00 Coronary artery spasm 
G33z.00 Angina pectoris NOS 
G33z000 Status anginosus 
G33z100 Stenocardia 
G33z200 Syncope anginosa 
G33z300 Angina on effort 
G33z400 Ischaemic chest pain 
G33z500 Post infarct angina 
G33z600 New onset angina 
G33z700 Stable angina 
G33zz00 Angina pectoris NOS 
G34..00 Other chronic ischaemic heart disease 
G340.00 Coronary atherosclerosis 
G340.11 Triple vessel disease of the heart 
G340.12 Coronary artery disease 
G340000 Single coronary vessel disease 
G340100 Double coronary vessel disease 
G341.00 Aneurysm of heart 
G341.11 Cardiac aneurysm 
G341000 Ventricular cardiac aneurysm 
G341100 Other cardiac wall aneurysm 
G341111 Mural cardiac aneurysm 
G341200 Aneurysm of coronary vessels 
G341300 Acquired atrioventricular fistula of heart 
G341z00 Aneurysm of heart NOS 
G342.00 Atherosclerotic cardiovascular disease 
G343.00 Ischaemic cardiomyopathy 
G344.00 Silent myocardial ischaemia 
G34y.00 Other specified chronic ischaemic heart disease 
G34y000 Chronic coronary insufficiency 
G34y100 Chronic myocardial ischaemia 
G34yz00 Other specified chronic ischaemic heart disease NOS 
G34z.00 Other chronic ischaemic heart disease NOS 
G34z000 Asymptomatic coronary heart disease 
G35..00 Subsequent myocardial infarction 
G350.00 Subsequent myocardial infarction of anterior wall 
G351.00 Subsequent myocardial infarction of inferior wall 
G353.00 Subsequent myocardial infarction of other sites 
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G35X.00 Subsequent myocardial infarction of unspecified site 
G36..00 Certain current complication follow acute myocardial infarct 
G360.00 Haemopericardium/current comp folow acut myocard infarct 
G361.00 Atrial septal defect/curr comp folow acut myocardal infarct 
G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn 
G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct 
G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
G37..00 Cardiac syndrome X 
G38..00 Postoperative myocardial infarction 
G380.00 Postoperative transmural myocardial infarction anterior wall 
G381.00 Postoperative transmural myocardial infarction inferior wall 
G382.00 Postoperative transmural myocardial infarction other sites 
G383.00 Postoperative transmural myocardial infarction unspec site 
G384.00 Postoperative subendocardial myocardial infarction 
G38z.00 Postoperative myocardial infarction, unspecified 
G39..00 Coronary microvascular disease 
G3y..00 Other specified ischaemic heart disease 
G3z..00 Ischaemic heart disease NOS 
Gyu3.00 [X]Ischaemic heart diseases 
Gyu3000 [X]Other forms of angina pectoris 
Gyu3100 [X]Other current complicatns following acute myocard infarct 
Gyu3200 [X]Other forms of acute ischaemic heart disease 
Gyu3300 [X]Other forms of chronic ischaemic heart disease 
Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
Gyu3500 [X]Subsequent myocardial infarction of other sites 
Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
 
Heart Failure 
 
Clinical 
Code Description 
1O1..00 Heart failure confirmed 
2JZ..00 On optimal heart failure therapy 
662f.00 New York Heart Association classification - class I 
662g.00 New York Heart Association classification - class II 
662h.00 New York Heart Association classification - class III 
662i.00 New York Heart Association classification - class IV 
8B29.00 Cardiac failure therapy 
G58..00 Heart failure 
G58..11 Cardiac failure 
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G580.00 Congestive heart failure 
G580.11 Congestive cardiac failure 
G580.12 Right heart failure 
G580.13 Right ventricular failure 
G580.14 Biventricular failure 
G580000 Acute congestive heart failure 
G580100 Chronic congestive heart failure 
G580200 Decompensated cardiac failure 
G580300 Compensated cardiac failure 
G580400 Congestive heart failure due to valvular disease 
G581.00 Left ventricular failure 
G581.11 Asthma - cardiac 
G581.13 Impaired left ventricular function 
G581000 Acute left ventricular failure 
G582.00 Acute heart failure 
G583.00 Heart failure with normal ejection fraction 
G583.11 HFNEF - heart failure with normal ejection fraction 
G583.12 Heart failure with preserved ejection fraction 
G584.00 Right ventricular failure 
G58z.00 Heart failure NOS 
G58z.12 Weak heart 
G5y4z00 Post cardiac operation heart failure NOS 
661M500 Heart failure self-management plan agreed 
661N500 Heart failure self-management plan review 
662p.00 Heart failure 6 month review 
662T.00 Congestive heart failure monitoring 
662W.00 Heart failure annual review 
679W100 Education about deteriorating heart failure 
8H2S.00 Admit heart failure emergency 
8HBE.00 Heart failure follow-up 
8HTL000 Referral to rapid access heart failure clinic 
G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G581.12 Pulmonary oedema - acute 
G58z.11 Weak heart 
SP11111 Heart failure as a complication of care 
SP11200 Cardiorespiratory failure as a complication of care 
G554000 Congestive cardiomyopathy 
 
Peripheral Vascular Disease 
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Clinical 
Code 
Description 
7A11211 Y graft of abdominal Aortic aneurysm (emergency) 
7A11311 Y graft of abdominal Aortic aneurysm (emergency) 
7A13.11 Emergency repair of aortic aneurysm 
7A13411 Tube graft abdominal Aortic aneurysm (emergency) 
7A14.11 Aortic aneurysm repair 
7A14411 Tube graft of Abdominal aortic aneurysm 
C107.12 Diabetes with gangrene 
G71..00 Aortic aneurysm 
G710.00 Dissecting aortic aneurysm 
G711.00 Thoracic aortic aneurysm which has ruptured 
G711.11 Ruptured thoracic aortic aneurysm 
G712.00 Thoracic aortic aneurysm without mention of rupture 
G713.00 Abdominal aortic aneurysm which has ruptured 
G713.11 Ruptured abdominal aortic aneurysm 
G713000 Ruptured suprarenal aortic aneurysm 
G714.00 Abdominal aortic aneurysm without mention of rupture 
G714.11 AAA - Abdominal aortic aneurysm without mention of rupture 
G714000 Juxtarenal aortic aneurysm 
G714100 Inflammatory abdominal aortic aneurysm 
G715.00 Ruptured aortic aneurysm NOS 
G715000 Thoracoabdominal aortic aneurysm, ruptured 
G716.00 Aortic aneurysm without mention of rupture NOS 
G716000 Thoracoabdominal aortic aneurysm, without mention of rupture 
G718.00 Leaking abdominal aortic aneurysm 
G71z.00 Aortic aneurysm NOS 
G73..00 Other peripheral vascular disease 
G73..11 Peripheral ischaemic vascular disease 
G731100 Vibratory white finger 
G732.00 Peripheral gangrene 
G732000 Gangrene of toe 
G732100 Gangrene of foot 
G732200 Gangrene of finger 
G732300 Gangrene of thumb 
G732400 Gangrene of hand 
G73y.00 Other specified peripheral vascular disease 
G73yz00 Other specified peripheral vascular disease NOS 
G73z.00 Peripheral vascular disease NOS 
G73z000 Intermittent claudication 
G73z011 Claudication 
G73zz00 Peripheral vascular disease NOS 
Gyu7100 [X]Aortic aneurysm of unspecified site, ruptured 
Gyu7200 [X]Aortic aneurysm of unspecified site, nonruptured 
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Gyu7400 [X]Other specified peripheral vascular diseases 
R054.00 [D]Gangrene 
R054000 [D]Gangrene, spreading cutaneous 
R054200 [D]Gangrene of toe in diabetic 
R054300 [D]Widespread diabetic foot gangrene 
R054z00 [D]Gangrene NOS 
G714200 Infrarenal abdominal aortic aneurysm 
G714300 Aneurysm of suprarenal aorta 
G717.00 Aortic aneurysm - syphilitic 
G71A.00 Aortic root dilatation 
G72..00 Other aneurysm 
G720.00 Aneurysm of artery of arm 
G720000 Aneurysm of brachial artery 
G720100 Aneurysm of radial artery 
G720200 Aneurysm of ulnar artery 
G720z00 Aneurysm of arm artery NOS 
G721.00 Aneurysm of renal artery 
G721000 Acquired renal artery aneurysm 
G721100 Congenital renal artery aneurysm 
G722.00 Aneurysm of iliac artery 
G722000 Aneurysm of common iliac artery 
G722100 Aneurysm of external iliac artery 
G722200 Aneurysm of internal iliac artery 
G722z00 Aneurysm of iliac artery NOS 
G723.00 Aneurysm of leg artery 
G723000 Aneurysm of femoral artery 
G723100 Aneurysm of popliteal artery 
G723200 Aneurysm of anterior tibial artery 
G723300 Aneurysm of dorsalis pedis artery 
G723400 Aneurysm of posterior tibial artery 
G723500 Ruptured popliteal artery aneurysm 
G723z00 Aneurysm of leg artery NOS 
G725.00 Dissection of artery of upper extremity 
G725.11 Dissection of artery of arm 
G726.00 Dissection of renal artery 
G727.00 Dissection of iliac artery 
G728.00 Dissection of artery of lower extremity 
G728.11 Dissection of artery of leg 
G729.00 Aneurysm and dissection of precerebral artery 
G72A.00 Dissection of other specified arteries 
G72B.00 Dissection of artery 
G72B000 Dissection of transplant artery 
G72y.00 Aneurysm of other artery 
G72y000 Aneurysm of common carotid art 
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G72y100 Aneurysm of external carotid artery 
G72y200 Aneurysm of internal carotid artery 
G72y300 Aneurysm of neck artery NOS 
G72y400 Aneurysm of subclavian artery 
G72y500 Aneurysm of splenic artery 
G72y600 Aneurysm of axillary artery 
G72y700 Aneurysm of coeliac artery 
G72y800 Aneurysm of superior mesenteric artery 
G72y900 Aneurysm of inferior mesenteric artery 
G72yA00 Aneurysm of hepatic artery 
G72yB00 Aneurysm of other visceral artery 
G72yz00 Vertebral artery aneurysm 
G72z.00 Other aneurysm NOS 
G73..12 Ischaemia of legs 
G73..13 Peripheral ischaemia 
G731.00 Raynaud's syndrome 
G731000 Raynaud's disease 
G731z00 Thromboangiitis obliterans NOS 
G733.00 Ischaemic foot 
G734.00 Peripheral arterial disease 
G73y000 Diabetic peripheral angiopathy 
G73y100 Peripheral angiopathic disease EC NOS 
G73y200 Acrocyanosis 
G73z012 Vascular claudication 
G73z100 Spasm of peripheral artery 
Gyu7300 [X]Aneurysm of other specified arteries 
14AE.00 H/O: aortic aneurysm 
14NB.00 H/O: Peripheral vascular disease procedure 
2I16.00 O/E - gangrene 
g71..00 Aortic aneurysm 
 
Stroke/Trans-ischaemic attack  
 
Clinical 
code 
Description 
G6...00 Cerebrovascular disease 
G60..00 Subarachnoid haemorrhage 
G600.00 Ruptured berry aneurysm 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
G602.00 Subarachnoid haemorrhage from middle cerebral artery 
G603.00 Subarachnoid haemorrhage from anterior communicating artery 
G604.00 Subarachnoid haemorrhage from posterior communicating artery 
G605.00 Subarachnoid haemorrhage from basilar artery 
G606.00 Subarachnoid haemorrhage from vertebral artery 
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G60X.00 Subarachnoid haemorrh from intracranial artery, unspecif 
G60z.00 Subarachnoid haemorrhage NOS 
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G617.00 Intracerebral haemorrhage, intraventricular 
G618.00 Intracerebral haemorrhage, multiple localized 
G619.00 Lobar cerebral haemorrhage 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G62..00 Other and unspecified intracranial haemorrhage 
G620.00 Extradural haemorrhage - nontraumatic 
G621.00 Subdural haemorrhage - nontraumatic 
G622.00 Subdural haematoma - nontraumatic 
G623.00 Subdural haemorrhage NOS 
G62z.00 Intracranial haemorrhage NOS 
G63..00 Precerebral arterial occlusion 
G63..11 Infarction - precerebral 
G63..12 Stenosis of precerebral arteries 
G630.00 Basilar artery occlusion 
G631.00 Carotid artery occlusion 
G631.11 Stenosis, carotid artery 
G631.12 Thrombosis, carotid artery 
G632.00 Vertebral artery occlusion 
G633.00 Multiple and bilateral precerebral arterial occlusion 
G634.00 Carotid artery stenosis 
G63y.00 Other precerebral artery occlusion 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
G63y100 Cerebral infarction due to embolism of precerebral arteries 
G63z.00 Precerebral artery occlusion NOS 
G64..00 Cerebral arterial occlusion 
G64..11 CVA - cerebral artery occlusion 
G64..12 Infarction - cerebral 
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G64..13 Stroke due to cerebral arterial occlusion 
G640.00 Cerebral thrombosis 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G641.00 Cerebral embolism 
G641.11 Cerebral embolus 
G641000 Cerebral infarction due to embolism of cerebral arteries 
G64z.00 Cerebral infarction NOS 
G64z.11 Brainstem infarction NOS 
G64z.12 Cerebellar infarction 
G64z000 Brainstem infarction 
G64z100 Wallenberg syndrome 
G64z111 Lateral medullary syndrome 
G64z200 Left sided cerebral infarction 
G64z300 Right sided cerebral infarction 
G64z400 Infarction of basal ganglia 
G65..00 Transient cerebral ischaemia 
G65..11 Drop attack 
G65..12 Transient ischaemic attack 
G65..13 Vertebro-basilar insufficiency 
G650.00 Basilar artery syndrome 
G650.11 Insufficiency - basilar artery 
G651.00 Vertebral artery syndrome 
G651000 Vertebro-basilar artery syndrome 
G652.00 Subclavian steal syndrome 
G653.00 Carotid artery syndrome hemispheric 
G654.00 Multiple and bilateral precerebral artery syndromes 
G655.00 Transient global amnesia 
G656.00 Vertebrobasilar insufficiency 
G657.00 Carotid territory transient ischaemic attack 
G65y.00 Other transient cerebral ischaemia 
G65z.00 Transient cerebral ischaemia NOS 
G65z000 Impending cerebral ischaemia 
G65z100 Intermittent cerebral ischaemia 
G65zz00 Transient cerebral ischaemia NOS 
G66..00 Stroke and cerebrovascular accident unspecified 
G66..11 CVA unspecified 
G66..12 Stroke unspecified 
G66..13 CVA - Cerebrovascular accident unspecified 
G660.00 Middle cerebral artery syndrome 
G661.00 Anterior cerebral artery syndrome 
G662.00 Posterior cerebral artery syndrome 
G663.00 Brain stem stroke syndrome 
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G664.00 Cerebellar stroke syndrome 
G665.00 Pure motor lacunar syndrome 
G666.00 Pure sensory lacunar syndrome 
G667.00 Left sided CVA 
G668.00 Right sided CVA 
G669.00 Cerebral palsy, not congenital or infantile, acute 
G67..00 Other cerebrovascular disease 
G670.00 Cerebral atherosclerosis 
G670.11 Precerebral atherosclerosis 
G671.00 Generalised ischaemic cerebrovascular disease NOS 
G671000 Acute cerebrovascular insufficiency NOS 
G671100 Chronic cerebral ischaemia 
G671z00 Generalised ischaemic cerebrovascular disease NOS 
G672.00 Hypertensive encephalopathy 
G672.11 Hypertensive crisis 
G673.00 Cerebral aneurysm, nonruptured 
G673000 Dissection of cerebral arteries, nonruptured 
G673100 Carotico-cavernous sinus fistula 
G673200 Carotid artery dissection 
G673300 Vertebral artery dissection 
G674.00 Cerebral arteritis 
G674000 Cerebral amyloid angiopathy 
G675.00 Moyamoya disease 
G676.00 Nonpyogenic venous sinus thrombosis 
G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
G677.00 Occlusion/stenosis cerebral arts not result cerebral infarct 
G677000 Occlusion and stenosis of middle cerebral artery 
G677100 Occlusion and stenosis of anterior cerebral artery 
G677200 Occlusion and stenosis of posterior cerebral artery 
G677300 Occlusion and stenosis of cerebellar arteries 
G677400 Occlusion+stenosis of multiple and bilat cerebral arteries 
G678.00 Cereb autosom dominant arteriop subcort infarcts leukoenceph 
G679.00 Small vessel cerebrovascular disease 
G67A.00 Cerebral vein thrombosis 
G67B.00 Reversible cerebral vasoconstriction syndrome 
G67B.11 Call-Fleming syndrome 
G67y.00 Other cerebrovascular disease OS 
G67z.00 Other cerebrovascular disease NOS 
G68..00 Late effects of cerebrovascular disease 
G680.00 Sequelae of subarachnoid haemorrhage 
G681.00 Sequelae of intracerebral haemorrhage 
G682.00 Sequelae of other nontraumatic intracranial haemorrhage 
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G683.00 Sequelae of cerebral infarction 
G68W.00 Sequelae/other + unspecified cerebrovascular diseases 
G68X.00 Sequelae of stroke,not specfd as h'morrhage or infarction 
G6y..00 Other specified cerebrovascular disease 
G6z..00 Cerebrovascular disease NOS 
Gyu6.00 [X]Cerebrovascular diseases 
Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
Gyu6100 [X]Other subarachnoid haemorrhage 
Gyu6200 [X]Other intracerebral haemorrhage 
Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
Gyu6400 [X]Other cerebral infarction 
Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
Gyu6700 [X]Other specified cerebrovascular diseases 
Gyu6C00 [X]Sequelae of stroke;not specfd as h'morrhage or infarction 
Gyu6D00 [X]Sequelae/other unspecified cerebrovascular diseases 
Gyu6E00 [X]Subarachnoid haemorrh from intracranial artery, unspecif 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
 
Hypertension 
 
Clinical 
Code Description 
G2...00 Hypertensive disease 
G2...11 BP - hypertensive disease 
G20..00 Essential hypertension 
G20..11 High blood pressure 
G20..12 Primary hypertension 
G200.00 Malignant essential hypertension 
G201.00 Benign essential hypertension 
G202.00 Systolic hypertension 
G203.00 Diastolic hypertension 
G20z.00 Essential hypertension NOS 
G20z.11 Hypertension NOS 
G21..00 Hypertensive heart disease 
G210.00 Malignant hypertensive heart disease 
G210000 Malignant hypertensive heart disease without CCF 
G210100 Malignant hypertensive heart disease with CCF 
G210z00 Malignant hypertensive heart disease NOS 
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G211.00 Benign hypertensive heart disease 
G211000 Benign hypertensive heart disease without CCF 
G211100 Benign hypertensive heart disease with CCF 
G211z00 Benign hypertensive heart disease NOS 
G21z.00 Hypertensive heart disease NOS 
G21z000 Hypertensive heart disease NOS without CCF 
G21z011 Cardiomegaly - hypertensive 
G21z100 Hypertensive heart disease NOS with CCF 
G21zz00 Hypertensive heart disease NOS 
G22..00 Hypertensive renal disease 
G22..11 Nephrosclerosis 
G220.00 Malignant hypertensive renal disease 
G221.00 Benign hypertensive renal disease 
G222.00 Hypertensive renal disease with renal failure 
G22z.00 Hypertensive renal disease NOS 
G22z.11 Renal hypertension 
G23..00 Hypertensive heart and renal disease 
G230.00 Malignant hypertensive heart and renal disease 
G231.00 Benign hypertensive heart and renal disease 
G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
G233.00 Hypertensive heart and renal disease with renal failure 
G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G23z.00 Hypertensive heart and renal disease NOS 
G24..00 Secondary hypertension 
G240.00 Secondary malignant hypertension 
G240000 Secondary malignant renovascular hypertension 
G240z00 Secondary malignant hypertension NOS 
G241.00 Secondary benign hypertension 
G241000 Secondary benign renovascular hypertension 
G241z00 Secondary benign hypertension NOS 
G244.00 Hypertension secondary to endocrine disorders 
G24z.00 Secondary hypertension NOS 
G24z000 Secondary renovascular hypertension NOS 
G24z100 Hypertension secondary to drug 
G24zz00 Secondary hypertension NOS 
G25..00 Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
G25..11 Stage 1 hypertension 
G250.00 Stage 1 hyperten (NICE 2011) without evidnce end organ damge 
G251.00 Stage 1 hyperten (NICE 2011) with evidnce end organ damge 
G26..00 Severe hypertension (Nat Inst for Health Clinical Ex 2011) 
G26..11 Severe hypertension 
G27..00 Hypertension resistant to drug therapy 
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G28..00 Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
G2y..00 Other specified hypertensive disease 
G2z..00 Hypertensive disease NOS 
Gyu2.00 [X]Hypertensive diseases 
Gyu2000 [X]Other secondary hypertension 
Gyu2100 [X]Hypertension secondary to other renal disorders 
 
Lipid Lowering Drugs 
 
Clinical 
code 
Description 
81048998 Atorvastatin 20mg chewable tablets sugar free 
81051998 Atorvastatin 10mg chewable tablets sugar free 
83099998 Simvastatin 40mg/5ml oral suspension sugar free 
82655998 Nicotinic acid & laropiprant 1g+20mg tablets 
83030998 Simvastatin 80mg tablets 
81050998 Atorvastatin 10mg chewable tablets sugar free 
84268998 Colesevelam 625mg tablets 
84267998 Colesevelam 625mg tablets 
83594998 Nicotinic acid 1g / laropiprant 20mg modified-release tablets 
79254979 Simvastatin 20mg/5ml oral suspension sugar free 
83188998 Bezafibrate 200mg tablets 
83187998 Bezafibrate 400mg modified-release tablets 
81049998 Atorvastatin 20mg chewable tablets sugar free 
82141978 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg 
capsules 
87853998 Nicotinic acid 1g modified-release tablets 
87852998 Nicotinic acid 500mg modified release tablets 
89154996 Cerivastatin 300microgram tablets 
86791998 Simvastatin 80mg / Ezetimibe 10mg tablets 
87854998 Nicotinic acid 750mg modified-release tablets 
89153996 Cerivastatin sodium 300mcg tablets 
88298997 Fenofibrate micronised 267mg capsules 
88534998 Rosuvastatin 10mg tablets 
86794998 Simvastatin 80mg / Ezetimibe 10mg tablets 
86510979 Ispaghula husk 3.5g sugar free granules 
87025998 Bezafibrate 400mg modified-release tablets 
87418998 Simvastatin 10mg tablets 
87918998 Simvastatin 10mg tablets 
89401998 Bezafibrate 400mg modified-release tablets 
87917998 Simvastatin 20mg tablets 
89089998 Bezafibrate 400mg modified release tablets 
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87373998 Simvastatin 10mg tablets 
87760998 Colestipol 5g granules sachets sugar free 
86798998 Simvastatin 20mg / Ezetimibe 10mg tablets 
88297996 Fenofibrate micronised 267mg capsules 
87848998 Nicotinic acid pack 
86796998 Simvastatin 40mg / Ezetimibe 10mg tablets 
87849998 Nicotinic acid 375mg + 500mg + 750mg modified-release tablet 
87850998 Nicotinic acid 1g modified release tablets 
87851998 Nicotinic acid 750mg modified release tablets 
86797998 Simvastatin 20mg / Ezetimibe 10mg tablets 
87916998 Simvastatin 40mg tablets 
89306996 Atorvastatin 40mg tablets 
89311998 Atorvastatin 10mg tablets 
89617998 Ispaghula husk 3.5g sugar free granules 
89154997 Cerivastatin 200microgram tablets 
86795998 Simvastatin 40mg / Ezetimibe 10mg tablets 
89311997 Atorvastatin 20mg tablets 
89306998 Atorvastatin 10mg tablets 
89311996 Atorvastatin 40mg tablets 
88298996 Fenofibrate micronised 200mg capsules 
86788998 Simvastatin 40mg / Ezetimibe 10mg tablets 
86789998 Simvastatin 20mg / Ezetimibe 10mg tablets 
89153998 Cerivastatin sodium 100mcg tablets 
86787998 Simvastatin 80mg / Ezetimibe 10mg tablets 
89154998 Cerivastatin 100microgram tablets 
88297998 Fenofibrate micronised 67mg capsules 
86467998 Rosuvastatin 5mg tablets 
89285979 Nicotinic acid 500mg modified release tablets 
89800998 
Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg 
capsules 
89284979 Nicotinic acid 750mg modified release tablets 
88298998 Fenofibrate micronised 67mg capsules 
88297997 Fenofibrate micronised 200mg capsules 
89306997 Atorvastatin 20mg tablets 
87855998 Nicotinic acid 500mg modified-release tablets 
89283979 Nicotinic acid 1g modified release tablets 
89153997 Cerivastatin sodium 200mcg tablets 
86468998 Rosuvastatin 5mg tablets 
92447998 Cerivastatin sodium 400mcg tablets 
90973998 Rosuvastatin 20mg tablets 
93619998 Simvastatin 10mg tablets 
92408998 Rosuvastatin 20mg tablets 
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93620996 Simvastatin 40mg tablets 
92448997 Cerivastatin 800microgram tablets 
92410998 Rosuvastatin 40mg tablets 
93620997 Simvastatin 20mg tablets 
93620998 Simvastatin 10mg tablets 
93871990 Simvastatin 40mg tablets 
92409998 Rosuvastatin 10mg tablets 
93243996 Pravastatin 40mg tablets 
91194998 Fluvastatin 80mg modified-release tablets 
93010990 Colestyramine 4g oral powder sachets sugar free 
92549990 Fenofibrate micronised 200mg capsules 
93244998 Pravastatin 10mg tablets 
93244997 Pravastatin 20mg tablets 
93244996 Pravastatin 40mg tablets 
92539998 Rosuvastatin 40mg tablets 
90310998 Atorvastatin 80mg tablets 
93243997 Pravastatin 20mg tablets 
92448998 Cerivastatin 400microgram tablets 
94407990 Simvastatin 20mg tablets 
93838990 Bezafibrate 200mg tablets 
92471998 Simvastatin 80mg tablets 
93851992 Colestipol 5g granules sachets sugar free 
90309998 Atorvastatin 80mg tablets 
92460998 Fenofibrate micronised 160mg tablets 
91316998 Colestyramine sugar free powder 
93243998 Pravastatin 10mg tablets 
92292998 Ezetimibe 10mg tablets 
92154990 Simvastatin 20mg/5ml oral suspension sugar free 
93541998 Colestyramine 4g oral powder sachets 
93542998 Colestyramine 4g oral powder sachets sugar free 
92804997 Fluvastatin 40mg capsules 
94189997 Fenofibrate micronised 200mg capsules 
92293998 Ezetimibe 10mg tablets 
90649998 Fenofibrate 200mg capsules 
92805998 Fluvastatin 20mg capsules 
92804998 Fluvastatin 20mg capsules 
92805997 Fluvastatin 40mg capsules 
93619996 Simvastatin 40mg tablets 
92220998 Simvastatin 80mg tablets 
90653998 Colestyramine 4g oral powder sachets sugar free 
94188997 Fenofibrate micronised 200mg capsules 
94112992 Cholestyramine 325 mg cap 
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94188998 Fenofibrate 100mg capsule 
94189998 Fenofibrate 100mg capsules 
92804996 Fluvastatin 80mg modified-release tablets 
93619997 Simvastatin 20mg tablets 
95480990 Simvastatin 10mg tablets 
95479990 Simvastatin 20mg tablets 
95952997 Bezafibrate 400mg modified-release tablets 
95550990 Simvastatin 20mg tablets 
95551990 Simvastatin 10mg tablets 
94925998 
Eicosapentaenoic acid 170mg / Docosahexaenoic acid 115mg 
capsules 
95478990 Simvastatin 40mg tablets 
95471990 Simvastatin 40mg tablets 
95475990 Simvastatin 20mg tablets 
94799998 Fenofibrate micronised 160mg tablets 
96295997 Gemfibrozil 600mg tablets 
95474990 Simvastatin 40mg tablets 
95472990 Simvastatin 20mg tablets 
95451990 Simvastatin 10mg tablets 
95549990 Simvastatin 40mg tablets 
96295998 Gemfibrozil 300mg capsules 
94927990 Simvastatin 80mg tablets 
94827992 Colestyramine 4g oral powder sachets 
95501990 Simvastatin 40mg tablets 
94782990 Pravastatin 20mg tablets 
95185990 Simvastatin 80mg tablets 
95494990 Simvastatin 20mg tablets 
94605998 Colestipol 5g granules sachets sugar free 
95495990 Simvastatin 10mg tablets 
94851990 Pravastatin 10mg tablets 
95500990 Simvastatin 80mg tablets 
94830990 Pravastatin 20mg tablets 
95502990 Simvastatin 20mg tablets 
97078998 Fish oil concentrate 1g capsules 
96685990 Bezafibrate 400mg modified-release tablets 
96685989 Bezafibrate 200mg tablets 
97377979 Cerivastatin sodium 300mcg tablets 
94831990 Pravastatin 10mg tablets 
97078997 Fish oil concentrate oral liquid 
94661998 Colestipol 5g granules sachets sugar free 
95482990 Simvastatin 20mg tablets 
95483990 Simvastatin 10mg tablets 
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95486990 Simvastatin 40mg tablets 
95508990 Simvastatin 10mg tablets 
95487990 Simvastatin 20mg tablets 
95952998 Bezafibrate 200mg tablets 
97078996 Fish oil concentrate oral emulsion 
94850990 Pravastatin 20mg tablets 
94849990 Pravastatin 40mg tablets 
94662998 Colestipol 5g granules sachets sugar free 
95493990 Simvastatin 40mg tablets 
95847990 Colestyramine 4g oral powder sachets sugar free 
95098992 Hexopal 200 mg tab 
97455979 Pravastatin 10mg tablets 
95481990 Simvastatin 40mg tablets 
94661997 Colestipol 5g granules sachets sugar free 
97430979 Fluvastatin 20mg capsules 
95805998 Bezafibrate 400mg modified release tablets 
95405990 Simvastatin 40mg tablets 
94789990 Pravastatin 10mg tablets 
95401998 Probucol 250mg tablet 
97247997 Gemfibrozil 600mg tablets 
97247998 Gemfibrozil 300mg capsules 
96134990 Colestyramine 4g oral powder sachets 
95278990 Simvastatin 20mg tablets 
95277990 Simvastatin 40mg tablets 
95372990 Simvastatin 40mg tablets 
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Table S2. The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using 
routinely collected health data. 
 
 Item 
No. 
STROBE items Location in 
manuscript where 
items are reported 
RECORD items Location in 
manuscript 
where items are 
reported 
Title and abstract  
 1 (a) Indicate the study’s design 
with a commonly used term in 
the title or the abstract (b) 
Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found 
Abstract RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be included. 
 
RECORD 1.2: If applicable, the 
geographic region and timeframe 
within which the study took place 
should be reported in the title or 
abstract. 
 
RECORD 1.3: If linkage between 
databases was conducted for the study, 
this should be clearly stated in the title 
or abstract. 
Abstract Study 
time has been 
noted in the study 
population 
section.  
Introduction 
Background 
rationale 
2 Explain the scientific 
background and rationale for the 
investigation being reported 
Introduction 
paragraphs 1-6 
  
Objectives 3 State specific objectives, 
including any prespecified 
hypotheses 
Introduction 
paragraph 7 
  
Methods 
Study Design 4 Present key elements of study 
design early in the paper 
Method: Study 
Design and Data 
Source 
  
Setting 5 Describe the setting, locations, 
and relevant dates, including 
Method: Study 
Population 
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periods of recruitment, exposure, 
follow-up, and data collection 
Participants 6 (a) Cohort study - Give the 
eligibility criteria, and the 
sources and methods of selection 
of participants. Describe 
methods of follow-up 
Case-control study - Give the 
eligibility criteria, and the 
sources and methods of case 
ascertainment and control 
selection. Give the rationale for 
the choice of cases and controls 
Cross-sectional study - Give the 
eligibility criteria, and the 
sources and methods of selection 
of participants 
 
(b) Cohort study - For matched 
studies, give matching criteria 
and number of exposed and 
unexposed 
Case-control study - For 
matched studies, give matching 
criteria and the number of 
controls per case 
Method: Study 
Population 
RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided.  
 
RECORD 6.2: Any validation studies 
of the codes or algorithms used to 
select the population should be 
referenced. If validation was conducted 
for this study and not published 
elsewhere, detailed methods and results 
should be provided. 
 
RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical display 
to demonstrate the data linkage 
process, including the number of 
individuals with linked data at each 
stage. 
Method: Study 
Population.  
No Validation 
studies were 
conducted for the 
use of the read 
codes in this 
study nor did this 
study include the 
use of linked 
datasets 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect 
modifiers. Give diagnostic 
criteria, if applicable. 
Method: Study 
Population 
RECORD 7.1: A complete list of codes 
and algorithms used to classify 
exposures, outcomes, confounders, and 
effect modifiers should be provided. If 
these cannot be reported, an 
explanation should be provided. 
Supplementary 
Materials 1 
Data sources/ 
measurement 
8 For each variable of interest, 
give sources of data and details 
of methods of assessment 
(measurement). 
Method Study 
Population 
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Describe comparability of 
assessment methods if there is 
more than one group 
Bias 9 Describe any efforts to address 
potential sources of bias 
Methods: Study 
design and data 
source, study 
population and 
statistical analysis 
  
Study size 10 Explain how the study size was 
arrived at 
Methods: Study 
Population 
  
Quantitative 
variables 
11 Explain how quantitative 
variables were handled in the 
analyses. If applicable, describe 
which groupings were chosen, 
and why 
Methods: Statistical 
analysis 
  
Statistical 
methods 
12 (a) Describe all statistical 
methods, including those used to 
control for confounding 
(b) Describe any methods used 
to examine subgroups and 
interactions 
(c) Explain how missing data 
were addressed 
(d) Cohort study - If applicable, 
explain how loss to follow-up 
was addressed 
Case-control study - If 
applicable, explain how 
matching of cases and controls 
was addressed 
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy 
(e) Describe any sensitivity 
analyses 
Methods: Statistical 
analysis 
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Data access and 
cleaning methods 
 ..  RECORD 12.1: Authors should 
describe the extent to which the 
investigators had access to the database 
population used to create the study 
population. 
 
RECORD 12.2: Authors should 
provide information on the data 
cleaning methods used in the study. 
Methods: Study 
Design and data 
source 
Linkage  ..  RECORD 12.3: State whether the 
study included person-level, 
institutional-level, or other data linkage 
across two or more databases. The 
methods of linkage and methods of 
linkage quality evaluation should be 
provided. 
Methods: Study 
Design and data 
source 
Results 
Participants 13 (a) Report the numbers of 
individuals at each stage of the 
study (e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in 
the study, completing follow-up, 
and analysed) 
(b) Give reasons for non-
participation at each stage. 
(c) Consider use of a flow 
diagram 
Results: baseline 
characteristics and 
table 1 
RECORD 13.1: Describe in detail the 
selection of the persons included in the 
study (i.e., study population selection) 
including filtering based on data 
quality, data availability and linkage. 
The selection of included persons can 
be described in the text and/or by 
means of the study flow diagram. 
Methods: Study 
Population 
Descriptive data 14 (a) Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information 
on exposures and potential 
confounders 
(b) Indicate the number of 
participants with missing data 
for each variable of interest 
Results: baseline 
characteristics and 
table 1 
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(c) Cohort study - summarise 
follow-up time (e.g., average and 
total amount) 
Outcome data 15 Cohort study - Report numbers 
of outcome events or summary 
measures over time 
Case-control study - Report 
numbers in each exposure 
category, or summary measures 
of exposure 
Cross-sectional study - Report 
numbers of outcome events or 
summary measures 
Results: Association 
between DA and 
Cardiometabolic 
disease and Table 2 
  
Main results 16 (a) Give unadjusted estimates 
and, if applicable, confounder-
adjusted estimates and their 
precision (e.g., 95% confidence 
interval). Make clear which 
confounders were adjusted for 
and why they were included 
(b) Report category boundaries 
when continuous variables were 
categorized 
(c) If relevant, consider 
translating estimates of relative 
risk into absolute risk for a 
meaningful time period 
Results: Association 
between DA and 
Cardiometabolic 
disease and Table 2 
  
Other analyses 17 Report other analyses done—
e.g., analyses of subgroups and 
interactions, and sensitivity 
analyses 
Nil other sensitivity 
analyses 
  
Discussion 
Key results 18 Summarise key results with 
reference to study objectives 
Discussion: 
Summary of key 
results 
  
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discussion: Study 
limitations 
RECORD 19.1: Discuss the 
implications of using data that were not 
created or collected to answer the 
Discussion: 
Summary of key 
results 
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Discuss both direction and 
magnitude of any potential bias 
specific research question(s). Include 
discussion of misclassification bias, 
unmeasured confounding, missing 
data, and changing eligibility over 
time, as they pertain to the study being 
reported. 
Interpretation 20 Give a cautious overall 
interpretation of results 
considering objectives, 
limitations, multiplicity of 
analyses, results from similar 
studies, and other relevant 
evidence 
Conclusion   
Generalisability 21 Discuss the generalisability 
(external validity) of the study 
results 
Conclusion   
Other Information 
Funding 22 Give the source of funding and 
the role of the funders for the 
present study and, if applicable, 
for the original study on which 
the present article is based 
Funding section   
Accessibility of 
protocol, raw 
data, and 
programming 
code 
 ..  RECORD 22.1: Authors should 
provide information on how to access 
any supplemental information such as 
the study protocol, raw data, or 
programming code. 
Data sharing and 
accessibility 
statement and 
supplementary 2 
 
*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working 
Committee.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement.  PLoS Medicine 2015; in 
press. 
 
*Checklist is protected under Creative Commons Attribution (CC BY) license. 
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